文献速递胸部肿瘤

芦比替定同情用药治疗广泛期小细胞肺癌的疗效与安全性:一项多中心国际队列研究

Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort.
PubMed 文献 · Eur J Cancer · 2025-07-03

该多中心国际队列纳入238例接受芦比替定同情用药的广泛期小细胞肺癌患者,二线占37%、三线占45%、更后线占18%。客观缓解率23.1%,疾病控制率45.5%,中位无进展生存期2.2个月,中位总生存期5.4个月。无化疗间期≥90天者无进展生存期与总生存期均更长。

要点

  • 客观缓解率23.1%,疾病控制率45.5%,中位无进展生存期2.2个月,中位总生存期5.4个月。
  • 无化疗间期≥90天者无进展生存期3.1个月 vs 1.8个月(HR 0.46),总生存期6.8个月 vs 4.5个月(HR 0.56)。
  • 218例(92%)记录到不良事件,其中29%为3-4级事件。

核心结论

  • 考虑到其安全性特征及适度但一致的有效性,芦比替定可作为广泛期小细胞肺癌患者同情用药的治疗选择,尤其是无化疗间期较长者。
  • 体能状态差、无化疗间期<90天、脑或肝转移可能影响总生存期。

研究设计与样本

  • 多中心国际队列研究,收集荷兰鹿特丹Erasmus医学中心与意大利帕多瓦Veneto肿瘤研究所所有接受芦比替定治疗的广泛期小细胞肺癌患者临床数据。
  • 共纳入238例接受芦比替定作为二线(37%)、三线(45%)或更后线(18%)治疗的患者。
  • 中位治疗周期数为3(范围1-22)。

主要发现

  • 客观缓解率为23.1%,疾病控制率为45.5%。
  • 中位无进展生存期为2.2个月(95%CI 1.6-2.8),中位总生存期为5.4个月(95%CI 4.5-6.3)。
  • 无化疗间期≥90天患者无进展生存期3.1个月 vs 1.8个月(HR 0.46,95%CI 0.30-0.71,p<0.001),总生存期6.8个月 vs 4.5个月(HR 0.56,95%CI 0.37-0.85,p=0.006)。
  • 开始芦比替定时ECOG体能状态≥2、脑转移或肝转移患者结局更差。
  • 218例(92%)记录到不良事件,其中29%为3-4级事件。

关键数值与推荐

  • 无化疗间期≥90天患者较<90天者无进展生存期延长(3.1 vs 1.8个月,HR 0.46,95%CI 0.30-0.71,p<0.001)。
  • 无化疗间期≥90天患者较<90天者总生存期延长(6.8 vs 4.5个月,HR 0.56,95%CI 0.37-0.85,p=0.006)。

临床怎么用

  • 芦比替定可作为广泛期小细胞肺癌患者同情用药的治疗选择,尤其是无化疗间期较长者。
  • 体能状态差、无化疗间期<90天、脑或肝转移可能影响总生存期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lurbinectedin has recently emerged in the treatment landscape of extensive stage (ES) small cell lung cancer (SCLC). Here we report the outcomes and safety of lurbinectedin within a named patient program in a multicentric, international cohort. METHODS: Clinical data of all patients with ES-SCLC treated with lurbinectedin at the Erasmus Medical Center (EMC, Rotterdam-The Netherlands) and the Veneto Institute of Oncology (IOV, Padua-Italy) were collected. RESULTS: A total of 238 patients receiving lurbinectedin as second- (37 %), third- (45 %) or further-line (18 %) were included. Median number of cycles was 3 (1-22). The objective response rate was 23.1 %, the disease control rate 45.5 %. The median progression free survival (PFS) 2.2 months (95 %CI 1.6-2.8) and the median overall survival (OS) 5.4 months (95 %CI 4.5-6.3). Patients with a chemotherapy-free interval (CFI) ≥ 90 days showed a longer PFS (3.1 vs 1.8 months, HR 0.46, 0.30-0.71, p < 0.001) and OS (6.8 vs 4.5 months, HR 0.56, 0.37-0.85, p = 0.006). Patients with ECOG performance status (PS) ≥ 2 at lurbinectedin start, brain or liver metastasis showed a worse outcome. Adverse events were recorded in 218 (92 %) patients, with 29 % grade 3-4 events. CONCLUSION: Considering its safety profile and modest but consistent effectiveness, lurbinectedin represents a therapeutic option as compassionate use in patients with ES-SCLC, especially in those with a long CFI. Poor PS, CFI < 90 days, brain or liver metastases may affect the OS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Scattolin D, Dingemans AC, Maso AD, et al. Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort. Eur J Cancer. 2025. PMID: 40618675. doi:10.1016/j.ejca.2025.115595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。